Kip P Conner
Overview
Explore the profile of Kip P Conner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bryniarski M, Tuhin M, Shomin C, Nasrollahi F, Ko E, Soto M, et al.
J Pharm Sci
. 2024 Jul;
113(10):3100-3111.
PMID: 39009346
Past studies have demonstrated higher clearance for monoclonal antibodies possessing increased rates of non-specific endocytosis. However, this metric is oftentimes evaluated indirectly using biophysical techniques or cell surface binding studies...
2.
Bryniarski M, Tuhin M, Acker T, Wakefield D, Sethaputra P, Cook K, et al.
J Pharm Sci
. 2024 Jun;
113(9):2879-2894.
PMID: 38906252
In vivo clearance mechanisms of therapeutic monoclonal antibodies (mAbs) encompass both target-mediated and target-independent processes. Two distinct determinants of overall mAb clearance largely separate of target-mediated influences are non-specific cellular...
3.
Liu S, Humphreys S, Cook K, Conner K, Correia A, Jacobitz A, et al.
MAbs
. 2023 Oct;
15(1):2263926.
PMID: 37824334
In this investigation, we tested the hypothesis that a physiologically based pharmacokinetic (PBPK) model incorporating measured metrics of off-target binding can largely explain the inter-antibody variability in monoclonal antibody (mAb)...
4.
Mock M, Jacobitz A, Langmead C, Sudom A, Yoo D, Humphreys S, et al.
MAbs
. 2023 Sep;
15(1):2256745.
PMID: 37698932
Biologic drug discovery pipelines are designed to deliver protein therapeutics that have exquisite functional potency and selectivity while also manifesting biophysical characteristics suitable for manufacturing, storage, and convenient administration to...
5.
You R, Artichoker J, Ray A, Gonzalez Velozo H, Rock D, Conner K, et al.
Cancer Immunol Res
. 2022 Apr;
10(6):698-712.
PMID: 35413104
Bispecific T-cell engager (BiTE) molecules are biologic T cell-directing immunotherapies. Blinatumomab is approved for treatment of B-cell malignancies, but BiTE molecule development in solid tumors has been more challenging. Here,...
6.
Conner K, Devanaboyina S, Thomas V, Rock D
Pharmacol Ther
. 2020 May;
212:107574.
PMID: 32433985
Therapeutic proteins (TPs) are a diverse drug class that include monoclonal antibodies (mAbs), recombinantly expressed enzymes, hormones and growth factors, cytokines (e.g. chemokines, interleukins, interferons), as well as a wide...
7.
Conner K, Pastuskovas C, Soto M, Thomas V, Wagner M, Rock D
MAbs
. 2020 Apr;
12(1):1746520.
PMID: 32310023
The decision to pursue a monoclonal antibody (mAb) as a therapeutic for disease intervention requires the assessment of many factors, such as target-biology, including the total target burden and its...
8.
Lockart M, Butler J, Mize C, Fair M, Cruce A, Conner K, et al.
J Inorg Biochem
. 2020 Jan;
205:110994.
PMID: 31982812
The Mycobacterium tuberculosis (Mtb) genome encodes 20 different cytochrome P450 enzymes (CYPs), many of which serve essential biosynthetic roles. CYP51B1, the Mtb version of eukaryotic sterol demethylase, remains a potential...
9.
Hamblett K, Le T, Rock B, Rock D, Siu S, Huard J, et al.
Mol Pharm
. 2016 Jun;
13(7):2387-96.
PMID: 27248573
Antibody-drug conjugates (ADC) rely on the target-binding specificity of an antibody to selectively deliver potent drugs to cancer cells. IgG antibody half-life is regulated by neonatal Fc receptor (FcRn) binding....
10.
Conner K, Cruce A, Krzyaniak M, Schimpf A, Frank D, Ortiz de Montellano P, et al.
Biochemistry
. 2015 Jan;
54(5):1198-207.
PMID: 25591012
Azoles and pyridines are commonly incorporated into small molecule inhibitor scaffolds that target cytochromes P450 (CYPs) as a strategy to increase drug binding affinity, impart isoform-dependent selectivity, and improve metabolic...